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Background: Familial partial lipodystrophies (FPLD) are clinically heterogeneous disorders characterized by selective
loss of adipose tissue, insulin resistance and metabolic complications. Until genetic studies become available for
clinical practice, clinical suspicion and pattern of fat loss are the only parameters leading clinicians to consider the
diagnosis. The objective of this study was to compare body composition by dual energy X-ray absorptiometry
(DXA) in patients with FPLD and control subjects, aiming to find objective variables for evaluation of FPLD.
Methods: Eighteen female patients with partial lipodystrophy phenotype and 16 healthy controls, matched for
body mass index, sex and age were studied. All participants had body fat distribution evaluated by DXA measures.
Fasting blood samples were obtained for evaluation of plasma leptin, lipid profile and inflammatory markers.
Genetic studies were carried out on the 18 patients selected that were included for statistical analysis. Thirteen
women confirmed diagnosis of Dunnigan-type FPLD (FPLD2).
Results: DXA revealed a marked decrease in truncal fat and 3 folds decrease in limbs fat percentage in FPLD2
patients (p <0.001). Comparative analysis showed that ratio between trunk and lower limbs fat mass, characterized
as Fat Mass Ratio (FMR), had a greater value in FLPD2 group (1.86 ± 0.43 vs controls 0.93 ± 0.10; p <0.001) and a
improved accuracy for evaluating FPLD2 with a cut-off point of 1.2. Furthermore, affected women showed
hypoleptinemia (FLPD2 4.9 ± 2.0 vs controls 18.2 ± 6.8; p <0.001), insulin resistance and a more aggressive lipid
profile.
Conclusion: In this study, assessment of body fat distribution by DXA permitted an objective characterization of
FLPD2. A consistent pattern with marked fat reduction of lower body was observed in affected patients. To our
knowledge this is the first time that cut-off values of objective variables were proposed for evaluation of FPLD2.
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Familial partial lipodystrophies (FPLD) are a clinically het-
erogeneous group of genetic disorders characterized by
variable loss of subcutaneous adipose tissue in extremities.
Affected patients exhibit insulin resistance and metabolic
complications [1,2]. Usually diagnosis is delayed and car-
diovascular disease is already established. Inappropriate fat* Correspondence: dracynthiavalerio@gmail.com
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reproduction in any medium, provided the ordistribution, not only reduction in the total amount of adi-
pose tissue, also contributes to the metabolic state [3]. Re-
cently, genetic research has improved our understanding
on the mechanisms underlying lipodystrophies, but some
patients with inherited forms do not have mutations in
the known lipodystrophy genes [4].
Until genetic studies become available for clinical prac-
tice, metabolic features and the pattern of adipose tissue
loss are the only parameters that may lead clinicians to
consider the diagnosis. To date few studies have compared
regional fat distribution in FPLD, most using Computed
Tomography or Magnetic Resonance Images [5-7], whichLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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suggested that DXA might be a tool for this purpose [8,9].
The ratio between truncal and lower limbs fat evaluated by
DXA, Fat Mass Ratio (FMR), has been proposed as a tool for
recognizing HIV-related lipodystrophy [10-12]. We previ-
ously reported the use of FMR in distinct forms of lipody-
strophy phenotypes, non-related to HIV infection [8,9].
Now, we have increased the number of studied patients and
limited it to Familial Partial Lipodystrophy (FPLD).
Patients and methods
In this study, we initially identified 18 women with partial
lipodystrophy phenotype selected from Metabolism Unit
of the State Institute of Diabetes and Endocrinology (Rio
de Janeiro, Brazil) using criteria from previous reports of
the syndrome [1,2]. All of them presented at least 3 of the
following features: postpuberal loss of adipose tissue
affecting lower limbs and sparing face and neck (essential
criteria) with prominent veins and muscularity, acanthosis
nigricans, polycystic ovarian syndrome (POS), hypertrigly-
ceridemia and/or low high-density-lipoprotein (HDL)-
cholesterol, diabetes mellitus type 2 (DM2) or impaired
fasting glucose (IFG). POS was defined by presence of oli-
gomenorrhea and hirsutism with no other known cause.
DM2 was identified as two fasting glucose≥ 126 mg/dl or
use of antidiabetic agents and IFG was characterized as
fasting glucose≥ 100 mg/dl or≥ 140 mg/dl after oral glu-
cose tolerance test. Hypertriglyceridemia was diagnosed
with triglycerides ≥150 mg/dl and low HDL-cholesterol
level was <50 mg/dl.
Exclusion criteria adopted were: age under 12 years,
pregnancy or breastfeeding, presence of acquired lipo-
distrophy (auto-immune or related to HIV infection or
use of Highly Active Antiretroviral Therapy), severe
renal or hepatic diseases, depression and alcoholism.
A control group with 16 healthy volunteers was
matched for age, sex and BMI with lipodystrophic group.
This group was recruited from outpatient clinic and hos-
pital employees and was not related to the patients.
Diagnosis of Dunnigan-type FPLD (FPLD2) was con-
firmed by molecular analysis of LMNA gene provided by
the Molecular Endocrinology Laboratory of the Univer-
sidade Federal de Sao Paulo. Thirteen women confirmed
diagnosis of FPLD2.
The Ethics Committee of the Institution approved the
protocol. A written informed consent was obtained from
each patient, after the procedures involved in the study
were fully explained.
Genetic studies
Screening for mutations of LMNA was done through
direct sequencing. Genomic DNA was extracted from
peripheral blood, with the commercial kit (Gentra Pure-
gene Blood Kit, Qiagen, Santa Clarita, CA, USA). Exons1–12 and the intron-exon boundaries of LMNA gene
were amplified by PCR using 14 pairs of primers. The
PCR products were directly sequenced with the use of
BigDyeW Terminator Cycle Sequencing Kit version 3.1
and analysed by ABI PRISM 3100 Genetic Analyzer
(Applied Biosystems, CA, USA).Anthropometrical examination
All participants were carefully examined by the same
endocrinologist and had the following anthropometrical
data registered: Body Weight (Kg), Height (m), Body
Mass Index (BMI), waist circumference (WC), waist-to-
hip ratio (WHR) and blood pressure. BMI was calculated
as weight in kilograms divided by the square of height in
meters (kg/m2). Waist circumference was determined at
the midpoint between the lowest rib and the iliac crest
in cm. WHR was defined as the ratio of waist girth to
the largest circumference of the hips, measured at the
trochanter major.Laboratory evaluation
Blood was collected after a 12 hour overnight fast in ap-
propriate tubes and assays for plasma leptin, glucose,
and lipoproteins. Plasma glucose was determined by
glucose-oxidase method. Cholesterol, lipoproteins frac-
tions and triglycerides were measured enzymatically.
Plasma leptin was measured by Radioimmunoassay
(Linco Research, Missouri, USA).Body fat analysis
DXA measurements of whole body, truncal and upper
limbs fat mass, as well as lower limbs fat mass were
obtained by DXA scan (LUNAR PRODIGY ADVANCE
software version 9.5, LNR 41569 model, GE Medical
Systems, Waukesha, WI). Central to peripheral fat Ratio
(or Fat Mass Ratio [FMR]) was used to investigate body
fat distribution [8,9]. Whole body DXA scans were
obtained using manufacturer’s recommendation for sub-
ject positioning, scan protocols and scan analysis.Statistical analysis
Statistical analysis was performed with SAS software
6.11 (SAS Institute, Inc., Cary, North Carolina, USA).
Unpaired t test was used for parametric variables and
Mann–Whitney for non-parametric variables. Statistical
analysis of subgroup with confirmed LMNA mutations
(FPLD2) and comparisons with the control group were
performed. The level of statistical significance was 5%.
The sensitivity and specificity of FMR in patients with
FPLD2 were calculated using receiver operating charac-
teristic curve (ROC) analysis.
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Genetic studies were carried out in the 18 female
patients with partial lipodystrophy phenotype. The thir-
teen women that confirmed diagnosis of Dunnigan-type
FPL (FPLD2) belonged to six different families. Family C
and E contributed with one case each; Family B with a
mother and her daughter; Family F and A with 2 and 3
sisters, respectively; and family D with 2 sisters and 2
cousins. All patients had a missense mutation in LMNA
gene: nine patients harbored the heterozygous variation
p. R482W; in three patients the mutation identified was
p.R482Q (c.1445 G>A) and one patient exhibited a
novel heterozygous variant in exon 8 (p.N466D) that we
previously reported [13]. The 5 remaining women that
underwent molecular biology studies showed no muta-
tions in the LMNA gene. They have not yet been genet-
ically tested for other lipodystrophy familial syndromes.
All of the FPLD2-affected women had acanthosis
nigricans and eight had the diagnosis of DM2. One is on
insulin therapy. Clinical features and metabolic status
are reported in Table 1. Nine out thirteen of LMNA-
mutated women had clinical phenotype of POS and
seven exhibited hypertension.
Table 2 presents the comparison of control group and
FPLD2 subjects. Despite the same age and BMI, lipody-
strophic group had significant differences in fat distribu-
tion as evaluated by DXA. A marked decrease in total,
as well as lower limbs fat mass was observed in affected
patients. On reverse, a substantial trunk fat deposition
was observed. Comparative analysis showed a greater
value of FMR in FLPD2 group (1.86 ± 0.43 vs controls
0.93 ± 0.10; p <0.001) and improved accuracy for evaluat-
ing FPLD2 with a cut-off point of 1.2. According to
values obtained by the ROC curve, the sensitivity and
specificity using these cut-off values were 88.9 and
93.8%, respectively. Comparison of FMR in both groups
is shown in Figure 1.
Furthermore, FPLD2-affected women showed hypoleptine-
mia (median of 4.4 vs 18.1 ng/ml in controls), insulin resist-
ance (8 out 13 had diabetes type 2 and two had impaired
fasting glucose) and an aggressive lipid profile with lower
levels of HDL-cholesterol (median of 36,5 versus 61,5 mg/dl
in controls) and hypertriglyceridemia (p=0.001).
Discussion
In this study, final diagnosis of FPLD2 was based on
genetic study. Once objective physical and metabolic fea-
tures that reliably define FPLD have not been identified,
we have used clinical and metabolic criteria described
from previous reports of the syndrome to initially select
our patients [1,2].
The main objective of this study was to find out if
body composition parameters utilizing DXA would be
useful for an objective evaluation of FPLD-affectedsubjects. Indeed, our data revealed a consistent pattern
of adipose tissue distribution, with marked fat reduction
of lower extremities and gluteal region (Table 2). This is
in agreement with what has been described in several
series of HIV patients [10-12]. Although scarcity of trun-
cal fat may not be a feature of FPLD2, it is noteworthy
that even when compared with BMI and age-matched
controls, affected group presented a marked reduction
of truncal body fat (44, 2 vs. 24, 5%). Interestingly, even
not harboring increased truncal fat, these patients are
severely metabolically compromised, suggesting that the
lack of adipose tissue in the lower body is the main fea-
ture for metabolic abnormalities. Indeed, studies have
suggested such a role for the peripheral fat in non-
lipodystrophic subjects [14-16]. Van Pelt et al. [14] con-
cluded that leg fat mass is associated with reduced CVD
risk, independently of increased risk attributable to
trunk fat mass. Tankó et al. [15] reached the same con-
clusion in a study using DXA for measuring fat distribu-
tion. In further support, Rocha et al. [16] revealed
independent and opposite association of hip circumfer-
ence with insulin resistance and atherothrombotic mar-
kers. Taken together, these findings underscore the
metabolic protective effect of lower-body adiposity.
We previously reported the use of FMR for identifica-
tion of all lipodystrophy phenotypes in a smaller series
of patients [8]. Now, we have increased the number of
studied patients and limited it to FLPD. Looking at the
Table 1, one can realize that only 3 patients with FPLD2
had FMR under 1.6. They were leaner and exhibited an
atypical form of FPLD2. Patient F-II, for example, is a
small lady, measuring 1.45 m, BMI 18,5 kg/m2 suffering
of a concomitant muscular dystrophy. On the other
hand, all the patients without LMNA mutation pre-
sented FMR under 1.7 and 2 out 5 presented FMR
within normal range. This finding suggests that FPLD2
subjects present higher values of FMR. Further studies
with larger samples are warranted to better characterize
body fat distribution in different types of FPLD.
In opposition to another anthropometric variables like
waist-to-hip circumference ratio or android-gynoid per-
centual fat ratio, FMR was the only densitometry param-
eter with a well-defined cut off-point (>1,2) and great
diagnostic accuracy for FLPD2. To our knowledge this is
the first series where FMR cut-off values were proposed
for evaluation of FPLD2. Bonnet et al. [10] were the first
authors to suggest the use of FMR in HIV-related lipo-
dystrophic patients, with a cut-off point of 1.3 +/−0.2.
Recently, another series performed in HIV-infected men
presented FMR >1.5 not only as a diagnostic criteria, but
also for assessment of clinical evolution of lipodystrophy
[11]. Therefore, our findings are in concordance with
data derived from HIV-related lipodystrophy and point
to the need of more studies in FLPD.
Table 1 Characteristics of study group subjects
Patient Age (y) LMNA
mutation
BMI
(kg/m2)
Clinical
lipoatrophy
Fat
deposition
DM2
(age of onset)
Dyslipidemia POS Comorbidities FMR
*A-I 44.5 p.R482Q 22,6 lower limbs face, neck IFG low HDL-c, Hypertrigl. yes HBP 1,8
*A-II 42.9 p.R482Q 22,6 four limbs face, neck 38 low HDL-c no HBP, CAD 2,38
*A-III 46.6 p.R482Q 23,1 lower limbs face, neck no low HDL-c, Hypertrigl. yes HBP 1,91
**B-I 14.7 p.R482W 22,1 slight, lower limbs no no no yes no 1,33
**B-II 27.9 p.R482W 27,6 four limbs face, neck,
supraclavicular
25 low HDL-c, Hypertrigl. yes no 1,71
C-I 26.3 p.R482W 27,4 four limbs face, neck,
supraclavicular
26 low HDL-c, Hypertrigl. yes Dilated
Miocardiopathy
2,53
***D-I 28.4 p.R482W 24,7 four limbs face, neck 22 low HDL-c, Hypertrigl. yes HBP 2,50
***D-II 31 p.R482W 20,5 slight, lower limbs no 29 low HDL-c, Hypertrigl. no HBP 1,81
***D-III 33 p.R482W 25,1 slight, lower limbs face, neck no low HDL-c, Hypertrigl. yes no 1,87
***D-IV 25.5 p.R482W 18,7 slight, lower limbs no no Hypertrigl. no no 1,28
E 19.4 p.N466D 28,1 four limbs, abdome face, neck 18 low HDL-c, Hypertrigl. yes HBP 1,62
****F-I 42 p.R482W 24,2 lower limbs trunk, face, neck 31 low HDL-c, Hypertrigl. yes HBP 2,25
****F-II 51.3 p.R482W 18,5 lower limbs no 28 low HDL-c, Hypertrigl. no muscular
dystrophy
1,3
G 38.7 no 45,5 lower limbs trunk 24 DM2, HDL-c,Hypertrigl Yes HBP 1,03
H 57.6 no 32,3 lower limbs trunk 27 DM2, HDL-c,Hypertrigl No HBP 1,35
I 60.2 no 34,3 lower limbs trunk no HDL-c,Hypertrigl yes HBP 1,04
J 56.8 no 32,5 lower limbs trunk 43 HDL-c,Hypertrigl yes HBP 1,64
K 48.6 no 31,1 Four limbs Trunk, neck 23 HDL-c,Hypertrigl Yes HBP 1,69
y- years.
FPLD- Familial Partial Lipodystrophy.
Low HDL-c- low HDL-cholesterol.
Hypertrig- Hypertriglyceridemia.
POS- Polycystic Ovarian Syndrome.
DM2- Type 2 Diabetes Mellitus.
IFG- Impaired Fasting Glucose.
CAD- Coronary Arterial Disease.
HBP- High Blood Pressure.
FMR- Fat Mass Ratio.
* Patients A-I, A-II and A-III are sisters and presented familial antecedents of a DM2, CAD and consanguinity.
** Patients B-I and B-II are mother and child.
***Patients D-I, D-II are siblings and cousins from D-III and D-IV. They present another relatives with partial lipodistrophy.
**** Patients F-I and e F-II are sisters and do not present another relatives with partial lipodistrophy.
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Köbberling variety of FPLD (FLPD1). On clinical basis,
the loss of adipose tissue in the Köberling variety is said
to be only restricted to extremities [17,18]. Patients have
normal amounts of fat in face and may have normal, or
even excess, subcutaneous truncal fat, as observed in the
5 of our patients without LMNA mutation. The genetic
defect associated with FPLD1 is currently unknown and
some authors postulate that it is likely a more common
FPLD than previously thought [19].
Another hypothesis for the 5 remaining women that
underwent molecular biology studies and showed no
mutations in the LMNA gene is the presence of PPARG
mutations, found in FPLD3 phenotype. As described by
Hegele et al., it appears that FPLD3, when compared
with FPLD2, is associated with less extensive adipose
loss, greater biochemical insulin resistance and moresevere and earlier clinical end points, such as POS, hep-
atic steatosis, DM2 [20]. Our findings are consistent
with this previous description, as depicted in Table 1.
FPLD2-affected women showed hypoleptinemia, insu-
lin resistance and a more aggressive lipid profile when
compared to control subjects. In general, there is a dir-
ect correlation between adipose mass and plasma leptin
concentration [21]. The decreased plasma leptin in
FPLD2 subjects results directly from the deficiency of
peripheral adipose tissue mass. Consistent with another
series, our results showed that the substantial, but in-
complete, adipose tissue loss in FPLD2 is compatible
with the observed reduction of mean plasma leptin to
approximately 40% of normal [22].
The current study has several limitations. First, we
were not able to search for another mutations linked to
lipodystrophy phenotypes (PPARG, AKT2, and PLIN1).
Table 2 Comparison of Anthropometric and DXA Measurements and Laborattory Evaluation in Patients with Familial
Partial Lipodystrophy (FPLD), Familial Partial Lipodystrophy Dunnigan-type (FPLD2) and Control Group
Control (n = 16) FLPD (n = 18) p FLPD2 (n = 13) p
Age (years) 40.6 ± 12.4 39.2 ± 14.5 0.73 33.3 ± 11.2 0.14
Waist (cm) 81.9 ± 9.2 82.3 ± 5.2 0.91 81.0 ± 7.2 0.89
Hip (cm) 103.1 ± 7.2 88.3 ± 5.4 <0.001 89.5 ± 5.0 <0.001
BMI (kg/m2) 25.6 ± 3.87 26.7 ± 6.6 0.76 23.5 ± 3.1 0.19
WHR 0.79 ± 0.06 0.94 ± 0.09 <0.001 0.90 ± 0.07 <0.001
Android/gynoid Fat Ratio 0.925± 0.1 1.177 <0.001 1.154 0.003
Total Fat (%) 43.6 ± 5.6 25.1 ± 11.0 <0.001 19.4 ± 4.9 <0.001
Troncular Fat (%) 44.2 ± 6.9 29.7 ± 11.0 <0.001 24.5 ± 6.2 <0.001
Upper Limbs Fat (%) 40.4 ± 5.2 22.9 ± 14.4 0.004 14.6 ± 5.1 <0.001
Lower Limbs Fat (%) 47.3 ± 5.6 19.4 ± 11.6 <0.001 13.7 ± 4.4 <0.001
Fat Mass (g) 28.5 ± 6.2 18.0 ± 12.0 0.002 11.7 ± 3.0 <0.001
Fat Mass Ratio (FMR) 0.93 ± 0.10 1.72 ± 0.46 <0.001 1.86 ± 0.43 <0.001
Leptin 18.1 ± 6.7 8.4 ± 9.0 <0.001 4.4 ± 2.1 <0.001
HDL Cholesterol 61.5 ± 13.4 39.4 ± 10.6 <0.001 36.5 ± 10.6 <0.001
LDL Cholesterol 126.3 ± 35.7 106.8 ± 38.9 0.20 110.7 ± 35.1 0.27
Triglycerides 109.3 ± 40.5 226.2 ± 115.3 <0.001 237.8 ± 130.6 <0.001
BMI = Body Mass Index; WHR=Waist-to-Hip Ratio.
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diagnosis. Second, our series only included female sub-
jects and our findings are not generalizable to men. In
addition, due to the rarity of the disease our small sam-
ple size limited our statistical analyses and correlations.
Further studies of body composition comparing FLPD
patients and controls are so warranted.FLPD 2CONTROLS
2,6
2,4
2,2
2,0
1,8
1,6
1,4
1,2
1,0
0,8
0,6
FM
R
p = 0,0001
Figure 1 Comparison of distribution of Fat Mass Ratio (+/- SD)
in control group and FLPD2 group.Conclusion
In this study, the comparison of body composition with
DXA in women with FPLD and healthy controls confirms
a fat distribution pattern with marked reduction in lower
extremities and gluteal region. A FMR cut-off point of 1.2
may be an objective and accurate index for the evaluation
of FLPD2. These findings supports that the hallmark of
FPLD2 is the lower-body fat reduction, that may be the
most important characteristic associated with the
increased cardio metabolic risk in these subjects.
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